Tag Archives: PD-1

B2M Gene Expression Shapes the Immune Landscape of Lung Adenocarcinoma and Determines the Response to Immunotherapy

Scientists performed an integrative analysis of the mutational and transcriptional profiles of large cohorts of non-small-cell lung cancer patients and found that epigenetic downregulation of B2M was common.
[Immunology]
Zhao, Y., Cao, Y., Chen, Y., Wu, L., Hang, H., Jiang, C., & Zhou, X. (n.d.). B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology, n/a(n/a). https://doi.org/10.1111/imm.13384 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Blocking Siglec-10hi Tumor-Associated Macrophages Improves Anti-Tumor Immunity and Enhances Immunotherapy for Hepatocellular Carcinoma

Immunohistochemistry and flow cytometry were performed to detect the characteristics of sialic acid-binding immunoglobulin-like lectin 10high (Siglec-10hi) tumor-associated macrophages and explore their impact on the tumor microenvironment of hepatocellular carcinoma.
[Experimental Hematology & Oncology]
Xiao, N., Zhu, X., Li, K., Chen, Y., Liu, X., Xu, B., Lei, M., Xu, J., & Sun, H.-C. (2021). Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. Experimental Hematology & Oncology, 10(1), 36. https://doi.org/10.1186/s40164-021-00230-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

T-Regulatory Cells Predict Clinical Outcome in Soft Tissue Sarcoma Patients: A Clinico-Pathological Study

Investigators analyzed tumor-infiltrating lymphocytes and immune checkpoint molecules in soft tissue sarcomas, and assessed their prognostic impact regarding local recurrence, distant metastasis, and overall survival.
[British Journal of Cancer]
Abstract
Bookmark

No account yet? Register

0
Share

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

Istari Oncology, Inc., announced that the US FDA has granted Fast Track designation to PVSRIPO for the improved survival in patients with advanced melanoma who have disease progression after anti-PD-1/anti-PD-L1 therapy.
[Istari Oncology, Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Phase I/II Clinical Trial of Adoptive Cell Transfer of Sorted Specific T Cells for Metastatic Melanoma Patients

Scientists reported results from a phase I/II clinical trial in which six metastatic HLA-A2 melanoma patients received autologous antigen-specific T-cells produced from peripheral blood mononuclear cells, after peptide stimulation in vitro, followed by sorting with HLA-peptide multimers and amplification.
[Cancer Immunology Immunotherapy]
Dréno, B., Khammari, A., Fortun, A., Vignard, V., Saiagh, S., Beauvais, T., Jouand, N., Bercegay, S., Simon, S., Lang, F., & Labarrière, N. (2021). Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-02961-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Tim-4+ Cavity-Resident Macrophages Impair Anti-Tumor CD8+ T Cell Immunity

The authors showed that metastatic disease in the pleural and peritoneal cavities is associated with poor clinical outcomes after immune checkpoint blockade therapy.
[Cancer Cell]
Chow, A., Schad, S., Green, M. D., Hellmann, M. D., Allaj, V., Ceglia, N., Zago, G., Shah, N. S., Sharma, S. K., Mattar, M., Chan, J., Rizvi, H., Zhong, H., Liu, C., Bykov, Y., Zamarin, D., Shi, H., Budhu, S., Wohlhieter, C., … Merghoub, T. (2021). Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell, 0(0). https://doi.org/10.1016/j.ccell.2021.05.006 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors

BeiGene, Ltd. announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental Biologics License Application for anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors.
[BeiGene, Ltd.]
Press Release
Bookmark

No account yet? Register

0
Share

Targeting Monoamine Oxidase A-Regulated Tumor-Associated Macrophage Polarization for Cancer Immunotherapy

Scientists observed monoamine oxidase A (MAO-A) induction in mouse and human tumor-associated macrophages (tAMs). MAO-A-deficient mice exhibit decreased TAM immunosuppressive functions corresponding with enhanced antitumor immunity.
[Nature Communications]
Wang, Y.-C., Wang, X., Yu, J., Ma, F., Li, Z., Zhou, Y., Zeng, S., Ma, X., Li, Y.-R., Neal, A., Huang, J., To, A., Clarke, N., Memarzadeh, S., Pellegrini, M., & Yang, L. (2021). Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nature Communications, 12(1), 3530. https://doi.org/10.1038/s41467-021-23164-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Synergistic Immunotherapy of Glioblastoma by Dual Targeting of IL-6 and CD40

Researchers identified a Stat3/HIF-1α-mediated axis, through which IL-6 executed an anti-tumor role to induce CD40 expression in Mϕs.
[Nature Communications]
Yang, F., He, Z., Duan, H., Zhang, D., Li, J., Yang, H., Dorsey, J. F., Zou, W., Ali Nabavizadeh, S., Bagley, S. J., Abdullah, K., Brem, S., Zhang, L., Xu, X., Byrne, K. T., Vonderheide, R. H., Gong, Y., & Fan, Y. (2021). Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nature Communications, 12(1), 3424. https://doi.org/10.1038/s41467-021-23832-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Genetic Variation Associated with Thyroid Autoimmunity Shapes the Systemic Immune Response to PD-1 Checkpoint Blockade

The authors studied endocrine immune related adverse events from seven clinical trials across six cancers where atezolizumab was combined with chemotherapies and compared to standard of care.
[Nature Communications]
Khan, Z., Hammer, C., Carroll, J., Di Nucci, F., Acosta, S. L., Maiya, V., Bhangale, T., Hunkapiller, J., Mellman, I., Albert, M. L., McCarthy, M. I., & Chandler, G. S. (2021). Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nature Communications, 12(1), 3355. https://doi.org/10.1038/s41467-021-23661-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Critical Role of the CD44lowCD62Llow CD8+ T Cell Subset in Restoring Antitumor Immunity in Aged Mice

Researchers investigated the role of T cell function in age-related unresponsiveness to PD-1 blockade cancer therapy. They found inefficient generation of CD44lowCD62Llow CD8+ T cell subset in draining lymph nodes of tumor-bearing aged mice.
[Proceedings of the National Academy of Sciences of the United States of America]
Nakajima, Y., Chamoto, K., Oura, T., & Honjo, T. (2021). Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice. Proceedings of the National Academy of Sciences, 118(23). https://doi.org/10.1073/pnas.2103730118 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share